Media ReleasesSUDA Pharmaceuticals

View All SUDA Pharmaceuticals News


SUDA Pharmaceuticals Placement Raises $3.65m


SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to announce that the Company has received firm commitments for a capital raising by placing up to 96,163,997 ordinary shares to institutional and sophisticated investors, raising $3,654,231 before costs. The news follows the 18 June 2021 announcement that SUDA has acquired an exclusive global licence to an invariant natural killer T (iNKT) cell therapy platform from Imperial College London.

The capital raising was completed at $0.038 per share, representing a premium to the closing price of shares on 17 June 2021 (the last trading day before announcing the Offer). SUDA intended to raise a minimum of $3,000,000 in the capital raising, and with the strong interest from institutional investors the Company agreed to raise $3,654,231. New shares issued under the Placement will rank equally with existing SUDA shares. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.